ModifiedPremera BluecrossPolicy N/A

Brand second-generation antidepressants (pharmacy prior authorization)

Defines medical necessity criteria and prior authorization requirements for single-source brand second-generation antidepressants (SSRIs, SNRIs, and other second-generation agents) under the pharmacy benefit; applies to providers submitting non-formulary/brand requests.

Policy Summary

PayerPremera Bluecross

PolicyBrand second-generation antidepressants (pharmacy prior authorization)

Policy CodePolicy N/A

Change TypeMultiple additions and removalsapproval-duration clarifications

Effective DateMay 1, 2026

Next Review DateN/A

Key ActionObtain and submit medical records documenting diagnosis, medication history, and prior generic trials to support prior authorization requests.

SourceLink

POLICY UPDATE CHANGES

Added Exxua (gepirone) coverage criteria for the treatment of depression.

Clarified that non-formulary exception review authorizations for all drugs listed in this policy may be approved up to 12 months.

Removed Cymbalta (duloxetine), Forfivo XL (bupropion ER), Symbyax (olanzapine and fluoxetine), and sertraline capsules from the policy as products were removed from the market or are now generic.

Combined depression and anxiety criteria into one table and added Length of Approval and Documentation Requirements table.

Removed Cymbalta (duloxetine), Forfivo XL (bupropion ER), and Symbyax (olanzapine and fluoxetine) from the policy as they were removed from the market.

Removed sertraline capsules from the policy as product is now generic.

Added brand escitalopram oxalate to policy for the treatment of anxiety and depression.

Added Exxua (gepirone) coverage criteria for the treatment of depression and later limited dose to 72.6 mg per day and prescribed quantity to 1 tablet per day.

Added Auvelity (dextromethorphan and bupropion) coverage criteria for the treatment of depression.

Added Raldesy (trazodone oral solution) for the treatment of depression.

Removed Remeron (mirtazapine) from the policy.

Clarified that the medications listed in this policy are subject to the product's FDA dosage and administration prescribing information.

Clarified that non-formulary exception review authorizations for all drugs listed in this policy may be approved up to 12 months.

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria for Brand Second-Generation Antidepressants

Initial Therapy / Diagnosis-specific criteria

Brand SSB second-generation antidepressants may be considered medically necessary when the following criteria for the relevant diagnosis are met.

Anxiety disorders - brand coverage: Brand SSRI/SNRI/second-generation antidepressant may be considered medically necessary for anxiety when ANY of the following are met: trial and failure of two generic SSRIs OR trial and failure of two generic SNRIs OR trial and failure of one generic SSRI and one generic SNRI.two generic trials (SSRIs or SNRIs) as specified

Examples of generic SSRIs: citalopram, escitalopram, fluoxetine, paroxetine, sertraline; examples of generic SNRIs: desvenlafaxine, duloxetine, venlafaxine

Depressive disorders - brand coverage: Brand SSRI/SNRI/second-generation antidepressant may be considered medically necessary for depressive disorders when the individual has had a trial and failure of two generic second-generation antidepressants.two generic second-generation antidepressant trials

Examples include fluoxetine, sertraline, venlafaxine, bupropion, mirtazapine.

Drug-specific limits

Exxua (gepirone) special limits: Coverage requires trial and failure of two generic second-generation antidepressants AND dose limited to 72.6 mg/day AND quantity limited to 1 tablet/day.72.6 mg/day; 1 tablet/day

Dose and quantity limits applied per policy history.

Formulation-specific criteria

Raldesy (trazodone oral solution) criteria: Covered when the individual has had a trial and failure of generic trazodone tablet OR documentation shows clinical necessity for oral solution (e.g., trouble swallowing).400 mg/day dose limit

Dose limited to 400 mg/day.

Policy updates and high‑level coverage stance

Policy updates describe covered and not medically necessary uses and approval durations.

policy structure: Combined depression and anxiety criteria are presented in a single table; all other uses of brand SSRI, SNRI, and second‑generation antidepressants are considered not medically necessary unless specified.

Length of Approval and Documentation Requirements table was added to policy.

new drug addition: Exxua (gepirone) added with coverage criteria for treatment of depression.

Added in 2024 update.

market removals: Cymbalta (duloxetine), Forfivo XL (bupropion ER), and Symbyax (olanzapine and fluoxetine) were removed from the policy due to market removal; sertraline capsules were removed as now generic.

Removals reflected in 2026 update.

Covered with criteria

Policy covers branded antidepressants when specific prior therapy and documentation criteria are met; other uses are not medically necessary.

General coverage stance: Branded SSRI, SNRI, and second-generation antidepressants are subject to medical necessity criteria, including prior trials of generically available agents; non-formulary exception reviews may be approved up to 12 months.

Providers must supply documentation per the Length of Approval and Documentation Requirements table.

All uses of medications not explicitly described as covered within this policy are considered not medically necessary. The policy notes: All other uses of the medications listed in this policy are considered not medically necessary. This applies to brand single‑source second‑generation antidepressants except where specific coverage criteria (e.g., diagnosis‑specific generic trial requirements, dose or quantity limits) are documented in the policy.

The policy explicitly states that uses of branded SSRIs, SNRIs, and other second‑generation antidepressants that are not listed in the policy tables are not medically necessary. The 2020 update added a table documenting that all other uses of brand SSRI, SNRI, and any second‑generation antidepressant for this policy are considered not medically necessary, unless specific criteria in the policy tables are met.

Per the policy history and coverage statements, all other uses of brand SSRI, SNRI, and any second‑generation antidepressant not specified in the policy are considered not medically necessary. Providers should rely on the policy tables for the list of covered indications and required supporting documentation; uses outside those specifications may be denied.

All uses of the medications that are not explicitly authorized by the policy are treated as not medically necessary. The policy language states: All other uses of the medications listed in this policy are considered not medically necessary.

The policy contains an explicit, unambiguous statement that requests for uses of listed medications that do not meet the documented coverage criteria will be considered not medically necessary. As noted in the coverage criteria section, "All other uses of the medications listed in this policy are considered not medically necessary." Providers must document compliance with the policy’s specific criteria (for example, required generic trials, dose or quantity limits) to support approval.

For this policy, any use of a branded SSRI, SNRI, or other second‑generation antidepressant that is not expressly covered in the policy tables is considered not medically necessary. The historical and recent updates clarify that only indications and drug‑specific conditions contained in the policy (including added dose/quantity limits and required prior generic trials) qualify for coverage.

Coding and Dose/Quantity Limits

Codingmixed

N/A	Coding: N/A

Covered/Managed through pharmacy benefitmixed

N/A	Policy notes medications are managed through the member's pharmacy benefit; coding section exists elsewhere in full policy.

inv-14: Exxua dose limit — 72.6 mg per day

Exxua (gepirone) maximum daily dose72.6 mg per day

Supporting policy statementExxua coverage requires trial and failure of two generic second-generation antidepressants and dose limited to 72.6 mg/day.

History of dose limitDose limit updated in 12/01/25 interim review and documented in policy history (updated Exxua criteria).

inv-15: Raldesy (trazodone oral solution) dose limit — 400 mg per day

Raldesy (trazodone oral solution) maximum daily dose400 mg per day

Coverage requirementCovered when patient has trial and failure of generic trazodone tablet OR documentation shows clinical necessity for oral solution (e.g., trouble swallowing).

Provider Actions, Authorization & Documentation Requirements

Prior Authorization

Prior Authorization Required

Prior authorization applies to the listed brand second‑generation antidepressants managed through the pharmacy benefit. This policy is enforced for pharmacy benefit contracts that include prior authorization edits; non‑formulary exception reviews may be considered.

Applies to branded SSRI, SNRI, and other second‑generation antidepressants listed in the policy
Managed through the member's pharmacy benefit; prior authorization edits apply to applicable pharmacy contracts

Denial Risk

Denial Triggers

Requests that do not meet the documented coverage criteria or that are for uses listed as not medically necessary may be denied. Examples of denial triggers include failure to document required prior generic trials, absence of a supported diagnosis, or insufficient clinical documentation of benefit from prior therapy.

Background and Rationale

Second‑generation antidepressants — including selective serotonin reuptake inhibitors (SSRIs), serotonin‑norepinephrine reuptake inhibitors (SNRIs), and related agents — are commonly used to treat depressive and anxiety disorders. Evidence summarized in the policy and its referenced literature indicates comparable efficacy across many agents and supports use of generic agents as first‑line. Consequently, this policy defines circumstances under which single‑source brand versions may be considered medically necessary, typically requiring documented trials and failures of specified generically available agents before brand approval. The policy’s rationale and literature reviews (periodic updates and history) informed expansion of indications from Major Depressive Disorder to broader Depressive Disorders and from Generalized Anxiety Disorder to Anxiety Disorders, and support the step‑therapy approach described in the coverage criteria.

Definitions and Initial Treatment Notes

inv-30: SSB second-generation antidepressant — definition: Single Source Brand (SSB) second-generation antidepressant

DefinitionSingle Source Brand (SSB) second-generation antidepressant

Drug classes includedSSRI, SNRI, and other second-generation antidepressants (agents other than tricyclic and MAOI).

Policy applicationPolicy applies to SSB versions of these agents under the pharmacy benefit; generics are generally tried first.

inv-31: Initial treatment recommendation — SSRI/SNRI first-line

Initial treatment recommendationSSRI or SNRI is recommended as first-line initial treatment for unipolar major depression.

Evidence sourceReviewed UpToDate (2022) supports SSRI/SNRI as initial treatment choice.

Initial Therapy Authorization Criteria

Initial therapy requirements

Initial authorization criteria

General initial requirement: Trial and failure of specified generic agents as described for the diagnosis (two generics for depression; for anxiety two generic SSRIs OR two generic SNRIs OR one SSRI and one SNRI).documented trials and failures of required generics

Documentation should include office visit notes with diagnosis, relevant history, physical evaluation and medication history.

Initial therapy — Historical step therapy requirements

Historical step therapy requirements

Historical step therapy: Historically the policy required trial and failure of two generically available second-generation antidepressants for Depressive Disorders; for Anxiety Disorders, trial and failure of two generically available SSRIs or one SSRI and one SNRI. Specific prior venlafaxine requirement was removed in 2015.

Re-authorization and Continuation Criteria

Re-authorization

Re-authorization requirements

Re-authorization for non-formulary exceptions: Non-formulary exception reviews may be renewed up to 12 months if medical necessity criteria are met and chart notes demonstrate continued positive clinical response; other reviews may be renewed up to 3 years under the same conditions.up to 12 months for non-formulary exceptions; up to 3 years for other reviews

Chart notes should document ongoing benefit and diagnosis.

Continuation therapy — Non-formulary exception authorizations and continuation rules

Continuation therapy and non‑formulary exception authorization rules

Continuation approvals: Non-formulary exception review authorizations for drugs listed in this policy may be approved up to 12 months; other reviews up to 3 years. Continuation requires documentation that the individual continues to show a positive clinical response to therapy.

Step Therapy Requirements

Diagnosis	Required generic trials before brand approval	Notes / limits
Anxiety disorders	Trial and failure of two generic SSRIs OR two generic SNRIs OR one generic SSRI and one generic SNRI	Examples of generic SSRIs: citalopram, escitalopram, fluoxetine, paroxetine, sertraline; examples of generic SNRIs: desvenlafaxine, duloxetine, venlafaxine
Depressive disorders	Trial and failure of two generic second-generation antidepressants	Examples include fluoxetine, sertraline, venlafaxine, bupropion, mirtazapine

Combined criteria (depression + anxiety)	Step / sequencing requirement	Policy note
Combined depression and anxiety criteria presented in single table	Follow diagnosis-specific sequencing: for depression two generic second-generation antidepressant trials; for anxiety two generic SSRIs OR two generic SNRIs OR one SSRI and one SNRI	All other uses of brand SSRI, SNRI, and second-generation antidepressants are considered not medically necessary unless specified
Policy historical context	Step therapy historically required trial and failure of two generically available agents; criteria have been consolidated into combined table	Length of Approval and Documentation Requirements table was added to policy

Indication group	Required generic trials (examples)	Coverage-limiting details
Depressive disorders	Trial and failure of two generic second-generation antidepressants (e.g., fluoxetine, sertraline, venlafaxine, bupropion, mirtazapine)	When criteria met, brand may be considered medically necessary; Exxua has additional dose/quantity limits (see drug-specific limits)
Anxiety disorders	Trial and failure of two generic SSRIs OR two generic SNRIs OR one generic SSRI and one generic SNRI (e.g., SSRIs: citalopram, escitalopram, fluoxetine, paroxetine, sertraline; SNRIs: desvenlafaxine, duloxetine, venlafaxine)	Brand coverage allowed only after required generic trials have failed

Quantity and Dispense Limits

inv-40: Exxua (gepirone) — 1 tablet

Exxua (gepirone) prescribed quantity1 tablet per day

Associated dose limitDose limited to 72.6 mg per day when quantity is 1 tablet/day.

Coverage requirementCoverage requires trial and failure of two generic second-generation antidepressants in addition to the quantity limit.

inv-41: Raldesy (trazodone oral solution) — 400 mg

Raldesy (trazodone oral solution) daily quantity/dose400 mg per day

Coverage conditionsCovered after trial and failure of generic trazodone tablet or if oral solution is clinically necessary (e.g., dysphagia).